Shanghai Fosun Pharmaceutical Reports Q1 2025 Earnings

Shanghai Fosun Pharmaceutical (Group) Co Class H ( (SFOSF) ) has released its Q1 earnings. Here is a breakdown of the information Shanghai Fosun Pharmaceutical (Group) Co Class H presented to its investors.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a Chinese joint stock company operating in the pharmaceutical industry, known for its focus on research, development, and manufacturing of medical products.

In its first quarterly report for 2025, Shanghai Fosun Pharmaceutical reported a decline in operating revenue to RMB 9.42 billion, attributed to changes in drug procurement contracts. However, the company saw a significant increase in net profit attributable to shareholders, reaching RMB 765 million, due to strategic asset disposals and financial asset value changes.

Key financial highlights include a 25.42% increase in net profit attributable to shareholders, despite a 7.26% decrease in operating revenue. The company also reported a 15.08% rise in net cash flow from operating activities, driven by improved supply chain management. The report highlighted the approval of innovative drugs like Serplulimab and Tenapanor, enhancing the company’s product portfolio.

Looking forward, Shanghai Fosun Pharmaceutical aims to continue its innovation transformation and international expansion, focusing on optimizing its asset structure and enhancing its R&D capabilities. The management remains committed to advancing its strategic goals and improving operational efficiency.